OverviewSuggest Edit

Pulse Biosciences is a medical technology company developing a novel tissue treatment platform based on its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation is a non-thermal, precise, focal drug-free tissue treatment technology that initiates cell death within treated tissue. NPS utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles. Once created, these transient nanopores allow ions to pass through these membranes, which disrupts cellular function and initiates cell death. NPS cell death eliminates treated tissue cells with a minimal inflammatory response, leading to a favorable healing process and the replacement of treated tissue cells with healthy tissue cells.

TypePublic
Founded2014
HQBurlingame, US
Websitepulsebiosciences.com

Latest Updates

Employees (est.) (Dec 2018)54(+64%)
Job Openings11
Share Price (Oct 2019)$14.1 (+4%)

Key People/Management at Pulse Biosciences

Darrin R. Uecker

Darrin R. Uecker

Chief Executive Officer, President & Director
Brian B. Dow

Brian B. Dow

Senior Vice President and Chief Financial Officer
Richard Nuccitelli

Richard Nuccitelli

Chief Science Officer
David Danitz

David Danitz

Vice President of Engineering
Ed Ebbers

Ed Ebbers

Vice President and General Manager of Dermatology
Holly Hartman

Holly Hartman

Vice President, Business Development and Corporate Strategy
Show more

Pulse Biosciences Office Locations

Pulse Biosciences has an office in Burlingame
Burlingame, US (HQ)
849 Mitten Rd #104
Show all (1)

Pulse Biosciences Financials and Metrics

Pulse Biosciences Revenue

USD

Net income (Q2, 2019)

(11.4m)

Market capitalization (15-Oct-2019)

293.0m

Closing stock price (15-Oct-2019)

14.1

Cash (30-Jun-2019)

10.8m
Pulse Biosciences's current market capitalization is $293 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

2.9m15.5m

R&D expense

6.0m9.6m

Operating expense total

9.6m25.8m

Depreciation and amortization

665.0k665.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

528.0k642.0k893.0k1.2m3.8m4.2m5.4m5.2m5.7m4.4m5.1m

R&D expense

990.0k1.5m1.7m1.9m2.3m3.2m3.2m4.0m5.0m5.8m6.3m

Operating expense total

1.7m2.3m2.8m3.2m6.2m7.5m8.7m9.3m10.9m10.4m11.6m

Depreciation and amortization

166.0k166.0k166.0k167.0k166.0k166.0k167.0k166.0k167.0k166.0k
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

2.1m3.4m51.1m

Inventories

268.0k

Current Assets

16.7m38.5m60.4m

PP&E

2.6m2.2m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

2.1m20.2m4.6m2.8m2.0m32.4m10.7m6.8m6.3m8.5m10.8m

Current Assets

2.6m21.0m19.0m19.1m16.1m42.6m33.7m28.7m22.1m53.4m44.6m

PP&E

2.7m2.6m2.5m2.4m2.3m2.1m2.0m

Goodwill

2.8m2.8m2.8m2.8m2.8m2.8m2.8m2.8m2.8m2.8m2.8m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(2.8b)(25.6m)(37.5m)

Depreciation and Amortization

167.0m336.0k1.3m

Inventories

12.0k

Accounts Payable

29.0k517.0k490.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.7m)(2.3m)(6.7m)(3.2m)(9.4m)(16.9m)(8.7m)(17.8m)(28.6m)(10.1m)(21.4m)

Depreciation and Amortization

166.0k166.0k166.0k166.0k196.0k319.0k642.0k973.0k329.0k633.0k

Accounts Payable

34.0k333.0k184.0k517.0k586.0k649.0k162.0k720.0k499.0k(72.0k)305.0k

Cash From Operating Activities

(1.5m)(5.7m)(2.5m)(3.7m)(7.1m)(5.0m)(10.7m)(17.6m)(7.3m)(17.0m)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Pulse Biosciences Operating Metrics

FY, 2016

Patent Applications

61

Patents Issued

49
Show all operating metrics

Pulse Biosciences Online and Social Media Presence

Embed Graph

Pulse Biosciences News and Updates

Pulse Biosciences Blogs

Pulse Biosciences Quarterly Investor Conference Call

Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and

Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Conference

Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Conference Content Import Tue, 08/06/2019 - 08:01 Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Conferen…

Pulse Biosciences to Report Second Quarter 2019 Operational Highlights and Financial Results

Pulse Biosciences to Report Second Quarter 2019 Operational Highlights and Financial Results Content Import Thu, 07/25/2019 - 16:20 Pulse Biosciences to Report Second Quarter 2019 Operational Highlights and Financial Results 07/25/19 This release is a backfill…

Research program explores energy for lesion treatment

Research program explores energy for lesion treatment renanjeff.lila… Thu, 06/13/2019 - 13:49 Research program explores energy for lesion treatment 05/14/19 This release is a backfill from a News Wire General View Dermatology Times ar…

Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference

HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 26, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ (NPS™) technology will be presented
Show more

Pulse Biosciences Frequently Asked Questions

  • When was Pulse Biosciences founded?

    Pulse Biosciences was founded in 2014.

  • Who are Pulse Biosciences key executives?

    Pulse Biosciences's key executives are Darrin R. Uecker, Brian B. Dow and Richard Nuccitelli.

  • How many employees does Pulse Biosciences have?

    Pulse Biosciences has 54 employees.

  • Who are Pulse Biosciences competitors?

    Competitors of Pulse Biosciences include Cook Medical, AxoGen and BioForce Nanosciences.

  • Where is Pulse Biosciences headquarters?

    Pulse Biosciences headquarters is located at 849 Mitten Rd #104, Burlingame.

  • Where are Pulse Biosciences offices?

    Pulse Biosciences has an office in Burlingame.

  • How many offices does Pulse Biosciences have?

    Pulse Biosciences has 1 office.